CD1a-Binding Antibodies for Targeted Inflammation Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for atopic dermatitis (AD) and inflammatory bowel disease (IBD) provide only temporary, incomplete symptom relief and often lead to adverse effects, highlighting a need for novel targeted therapies that address the underlying pathophysiology.

Innovation Solution

Development of antibodies and antigen-binding fragments that specifically bind to CD1a, targeting specific epitopes such as Glu82, His170, Ile92, and Arg93, with high affinity and low immunogenic potential, to modulate immune responses and provide therapeutic benefits.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (corticosteroids, H1-antihistamines) are used for atopic dermatitis, then symptom relief is provided, but long-term use leads to adverse effects including skin thinning, atrophy, and systemic side effects

Engineering Contradiction:

Improvesymptom relief effectivenessVSAvoidadverse effects (skin thinning, atrophy, systemic side effects)

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets the specific pathophysiological mechanism of AD by developing antibodies against CD1a, which is involved in T-cell activation and inflammation. This extracts the therapeutic action from broad-spectrum treatments to a targeted mechanism, providing symptom relief without the adverse effects of conventional treatments.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces CD1a-blocking antibodies as an intermediary substance that mediates the therapeutic effect by specifically blocking the CD1a pathway involved in AD pathogenesis. This intermediary approach replaces direct use of corticosteroids with a more selective mechanism that achieves symptom relief without their harmful side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Duration of action of moving object

If current treatments are used for atopic dermatitis, then temporary symptom relief is achieved, but treatment resistance develops and complete symptom relief is not obtained

Engineering Contradiction:

Improveduration of symptom reliefVSAvoidtreatment effectiveness

Core Design Contradiction:

Duration of action of moving objectVSReliability

Solution Approach 1:

The patent enables continuous therapeutic action by targeting the underlying pathophysiology through CD1a blockade. By addressing the root mechanism of T-cell activation and inflammation rather than just symptoms, the treatment maintains continuous effectiveness without developing resistance, providing both long duration and high reliability.

Inventive Principle:

Principle #20Continuity of useful action

3Adaptability or versatility

If broad-spectrum treatments are used for inflammatory diseases, then multiple symptoms are addressed, but the underlying pathophysiology is not targeted

Engineering Contradiction:

Improvebroad symptom coverageVSAvoidtreatment specificity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by directing therapeutic action specifically to the CD1a pathway involved in AD pathogenesis. Rather than using broad-spectrum treatments that affect multiple systems, the antibody treatment concentrates its effect on the specific molecular target driving the disease, achieving both specificity and effectiveness.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12528868B2CD1a antibodies and uses thereof

Publication Date: 2026.01.20 PFIZER INC

AI summary

Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.